Physician profile
Jeffrey Howard
NPI 1487682860
$3,567.35
in general payments reported to CMS, 2019-2025
21 companies · $432 in 2025
The $432 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $700 · 2020: $473 · 2021: $1,042 · 2022: $350 · 2023: $217 · 2024: $355 · 2025: $432.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,004.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,003.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $608.56 | 2019-2023 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $482.90 | 2019-2025 | Lifevest |
| Pfizer INC. | $430.11 | 2019-2025 | |
| Astellas Pharma US INC | $212.99 | 2021 | |
| Merck Sharp & Dohme LLC | $200.06 | 2021-2025 | Verquvo, Capvaxive |
| Novartis Pharmaceuticals Corporation | $190.42 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $185.32 | 2019-2024 | Farxiga |
| Abiomed | $184.24 | 2025 | |
| Amgen INC. | $157.47 | 2019-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $147.04 | 2019-2024 | Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $142.10 | 2022 | |
| Biotronik Nro, INC. | $133.90 | 2024 | Prospera |
| Esperion Therapeutics, INC. | $99.81 | 2020-2024 | Nexletol |
| Amarin Pharma, INC. | $88.13 | 2020-2021 | |
| Edwards Lifesciences Corporation | $87.11 | 2019-2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $59.04 | 2021-2025 | Amvuttra |
| Regeneron Healthcare Solutions, INC. | $58.47 | 2019 | |
| Lundbeck LLC | $44.11 | 2019 | |
| Abbott Laboratories | $24.45 | 2021 | |
| Cook Medical LLC | $16.69 | 2023 | Zilver Vena |
| Scpharmaceuticals INC. | $14.43 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Howard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.